Allianz Asset Management
SAGE

Allianz Asset Management’s Sage Therapeutics SAGE Stock Holding History

Allianz Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50,158
Closed -$1.03M – 2227
2023
Q3 		$1.03M Sell
50,158
-57,852
-54% -$1.67M ﹤0.01% 1693
2023
Q2 		$5.08M Sell
108,010
-8,163
-7% -$406K 0.01% 862
2023
Q1 		$4.87M Buy
116,173
+25,413
+28% +$1.09M 0.01% 980
2022
Q4 		$3.46M Buy
90,760
+34,812
+62% +$1.33M 0.01% 1072
2022
Q3 		$2.19M Buy
+55,948
New +$2.16M ﹤0.01% 1202
2021
Q4 		– Sell
-75,768
Closed -$3.36M – 2672
2021
Q3 		$3.36M Buy
75,768
+37,590
+98% +$1.72M ﹤0.01% 1448
2021
Q2 		$2.17M Sell
38,178
-12,730
-25% -$900K ﹤0.01% 1448
2021
Q1 		$3.81M Buy
50,908
+38,168
+300% +$3.13M ﹤0.01% 1166
2020
Q4 		$1.1M Buy
+12,740
New +$939K ﹤0.01% 1461
2020
Q1 		– Sell
-27,995
Closed -$2.02M – 2712
2019
Q4 		$2.02M Sell
27,995
-97,024
-78% -$11.9M ﹤0.01% 1870
2019
Q3 		$17.6M Sell
125,019
-10
-0% -$1.67K 0.02% 831
2019
Q2 		$22.9M Buy
125,029
+12,460
+11% +$2.13M 0.02% 754
2019
Q1 		$17.9M Buy
112,569
+87,665
+352% +$12.7M 0.02% 804
2018
Q4 		$2.34M Sell
24,904
-13,082
-34% -$1.5M ﹤0.01% 1709
2018
Q3 		$5.37M Hold
37,986
– – ﹤0.01% 1531
2018
Q2 		$5.95M Sell
37,986
-6,488
-15% -$1.02M 0.01% 1459
2018
Q1 		$7.16M Buy
44,474
+40,288
+962% +$6.84M 0.01% 1388
2017
Q4 		$689K Sell
4,186
-3,468
-45% -$336K ﹤0.01% 2341
2017
Q3 		$477K Buy
7,654
+3,076
+67% +$242K ﹤0.01% 2429
2017
Q2 		$365K Sell
4,578
-3,088
-40% -$223K ﹤0.01% 2476
2017
Q1 		$545K Buy
+7,666
New +$449K ﹤0.01% 2386
2015
Q4 		– Sell
-138,145
Closed -$5.85M – 2499
2015
Q3 		$5.85M Buy
138,145
+83,720
+154% +$5.16M 0.01% 1215
2015
Q2 		$3.97M Buy
+54,425
New +$3.5M ﹤0.01% 1456

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allianz Asset Management's SAGE Position: Q4 2023 in Review

Allianz Asset Management sold out of Sage Therapeutics (SAGE) in Q4 2023, closing a stake of 50,158 shares — an estimated $1.03M sold.

Allianz Asset Management first reported a position in SAGE in Q2 2015 and held it in 23 quarters. The position peaked at $22.9M in Q2 2019. 201 funds tracked by Wall St. Rank hold SAGE as of Q4 2023.

  • Allianz Asset Management reported no remaining Sage Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Allianz Asset Management sold 50,158 Sage Therapeutics shares in Q4 2023, an estimated $1.03M.
  • Allianz Asset Management first reported a position in Sage Therapeutics in Q2 2015 and held it in 23 quarters.
  • Allianz Asset Management's Sage Therapeutics position peaked at $22.9M in Q2 2019.
  • 201 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2023.

Based on Allianz Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.